FWBI keeps "Buy" rating at Roth - Cantech Letter
Following news of an acquisition, Roth MKM analyst Jonathan Aschoff remains bullish on First Wave BioPharma
Source: cantechletter.com
Jack Syage News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jack Syage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jack Syage Today - Breaking & Trending Today
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline
First Wave BioPharma Inc FWBI has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on…
Source: biztoc.com
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal disease clinical pipeline A concurrent institutional...
Source: marketscreener.com
First Wave BioPharma To Acquire ImmunogenX In All-stock Transaction
(RTTNews) - Biopharmaceutical company First Wave BioPharma, Inc. (FWBI) announced Monday that the company has signed a non-binding term sheet to a...
Source: businessinsider.com
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline - First Wave BioPharma (NASDAQ:FWBI)
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for gastrointestinal (GI) diseases.
Source: benzinga.com